Oculis (OCS) Expected to Post Earnings on Tuesday

Key Points

• Oculis is expected to report Q3 2026 results before the market opens on November 3. Analysts forecast a loss of $0.49 per share and revenue of approximately $0.25 million.
• The company reported a $0.20 per-share loss and $0.38 million in revenue in its prior quarter, while analysts expect full-year and next-year losses of $2.01 and $2.05 per share, respectively.
• Oculis shares recently traded near $8, substantially below their 12-month high of $34.47. Despite the decline, analyst sentiment remains a “Moderate Buy,” with an average price target of $39.44, though ratings range from “Sell” to “Buy.”

Oculis (NASDAQ:OCS - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.49) per share and revenue of $0.25 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 12:30 PM ET.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The company had revenue of $0.38 million during the quarter. On average, analysts expect Oculis to post ($2.01) EPS for the current fiscal year and ($2.05) EPS for the next fiscal year.

Oculis Trading Up 1.2%

Oculis stock traded up $0.10 during midday trading on Tuesday, reaching $8.00. The stock had a trading volume of 3,541 shares, compared to its average volume of 423,542. The stock's 50-day simple moving average is $10.16 and its 200 day simple moving average is $19.06. Oculis has a twelve month low of $7.11 and a twelve month high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The stock has a market capitalization of $463.72 million, a PE ratio of -4.58 and a beta of 0.62.

Analyst Ratings Changes

OCS has been the subject of several research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a report on Thursday, October 15th. Wall Street Zen upgraded shares of Oculis from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. HC Wainwright reiterated a "buy" rating and set a $39.00 target price on shares of Oculis in a research note on Wednesday, October 21st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Oculis has a consensus rating of "Moderate Buy" and an average target price of $39.44.

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.